IL13RA2 and prostate carcinoma: Even though several reports have indicated that many cytokines, their receptors, and cytokine signaling effectors are engaged in the metastatic process [74], our findings revealed that prostate cancer patients, which were specifically clustered for a low cumulative expression of IL13RA2, GDF7, IL33, CXCL1, TNFRSF19, CXCL6, LIFR, CXCL5, IL7, TSLP, and TNFSF15, display poor survival rates respect to patients showing high levels of the aforementioned genes.